Xconomy

JUNE 23, 2016

San Diego’s cybersecurity workforce has grown by nearly 15 percent over the past two years, according to a study released today by the Cyber Center of Excellence, a nonprofit industry group created to boost cybersecurity jobs and technologies in the region. The center also asked the San Diego Regional Economic Development Corp.

San Diego 69

San Diego Study Outsource Development Report 69

Xconomy

SEPTEMBER 18, 2018

Viking Therapeutics released preliminary results from a Phase 2 study suggesting its experimental drug might impact some of the disease’s many dangerous effects on the liver.

Study 76

Study San Diego Competition Report 76

Xconomy

AUGUST 31, 2016

Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological processes, has died, according to a statement from the university. Various Fluorescing Proteins. He compared himself to John C.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

JUNE 23, 2020

Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate.

San Diego 127

San Diego Study Design Develop 127

Xconomy

SEPTEMBER 15, 2016

The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County. Innovation Companies in San Diego (Courtesy Connect Innovation Report).

San Diego 40

San Diego Report High Tech Study 40

Xconomy

MAY 19, 2020

Amplyx Pharmaceuticals has completed enrollment in one mid-stage trial of its lead drug candidate, a new kind of antifungal treatment, and has finished treating the first patients in two more such studies.

San Diego 114

San Diego Funding Study Company 114

Xconomy

JUNE 3, 2019

That’s according to a new study from University of California, Berkeley data scientists who analyzed the records of more than 400,000 people in the United Kingdom.

Study 78

Study Sample Research San Diego 78

Xconomy

APRIL 7, 2020

The Plymouth Meeting, PA-based company, which also conducts research in San Diego, plans to enroll as many as 40 adults across two trial locations. Those enrolled in the study will get two doses of INO-4800. Inovio (NASDAQ: INO ) said Monday it anticipated dosing its first patient that day.

San Diego 108

San Diego Study Research Develop 108

Xconomy

MARCH 28, 2019

million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. Founders Jared Tagney and Joshua Windmiller, who met while in grad school at UC San Diego, started the company in 2012 as Electrozyme.

San Diego 103

San Diego Study Research Design 103

Xconomy

JULY 2, 2018

The test, sold by Genomic Health (NASDAQ: GHDX ) of Redwood City, CA, and developed by Epic Sciences of San Diego, is for men with a dangerous, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS. (Earlier this year, the federal insurance program Medicare sent positive signals about coverage but hasn’t made a final decision.)

Guide 81

Guide Study San Diego Journal 81

Xconomy

DECEMBER 18, 2019

More than 250 miles above the Earth’s surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

Research 90

Research San Diego Study Funding 90

Xconomy

OCTOBER 30, 2019

Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study. The FDA put a partial clinical hold on a Phase 1/2 study testing the therapy, Zolgensma, Novartis (NYSE: NVS ) announced Wednesday.

Study 49

Study San Diego Blogging 49

Xconomy

MAY 7, 2018

At the American Psychiatric Association conference today in New York, Assurex Health, a division of diagnostics firm Myriad Genetics (NASDAQ: MYGN ), is releasing data from a study of 1,167 people with serious depression, officially known as major depressive disorder, whom previous treatments have failed.

Study 65

Study Guide Conference Help 65

Xconomy

DECEMBER 6, 2019

But the San Diego-based company has also been testing the drug in dementia-related psychosis (DRP), which includes those with Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia patients who are experiencing hallucinations and delusions.

San Diego 98

San Diego Study Company Companies 98

Xconomy

OCTOBER 13, 2020

Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study.

San Diego 82

San Diego Study Develop Development 82

Xconomy

JULY 21, 2020

Since then, the San Diego company has looked to expand its use into other indications, with mixed results. The trial combined two studies that collectively enrolled about 300 patients with MDD. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 67

San Diego Study Report Company 67

Xconomy

JULY 2, 2020

MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping patients live longer.

San Diego 86

San Diego Study Help Company 86

Xconomy

NOVEMBER 11, 2019

A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder. The Basel, Switzerland-based company plans to present full data from the study at a future medical conference.

Study 49

Study Conference Help Develop 49

Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

DECEMBER 4, 2018

Take the results of a Phase 3 study just reported today at the American Society of Hematology’s (ASH) yearly meeting in San Diego. The treatment landscape for multiple myeloma, a deadly cancer of the bone marrow that affects about 30,000 Americans every year, has changed significantly over the past decade.

San Diego 83

San Diego Study Report Blogging 83

Xconomy

JUNE 28, 2017

A new study published Monday in the Annals of Internal Medicine questions the practicality of making DNA tests standard for people who don’t have a cancer diagnosis or aren’t trying to identify a mysterious disease. The study is limited by its small scope, but it is the first with some rigor to examine outcomes.

Study 62

Study Writing Help San Diego 62

Xconomy

JULY 6, 2016

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

Study 59

Study PMI San Diego Sample 59

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. The deal follows completion of a Phase 1 study evaluating the PvP drug. That day is here.

San Diego 72

San Diego Study Develop Development 72

Xconomy

NOVEMBER 26, 2018

This weekend, San Diego will host the annual American Society of Hematology conference, the largest U.S. [ Note: Ben Fidler co-authored this report.] medical gathering to get the latest on blood diseases, and a venue for updates on some of the most cutting-edge biotechnologies that only a few years ago seemed like science fiction.

Guide 96

Guide San Diego Study Conference 96

Xconomy

AUGUST 22, 2019

The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN.

San Diego 79

San Diego Study Marketing Develop 79

Xconomy

OCTOBER 1, 2018

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

Xconomy

SEPTEMBER 24, 2018

Roche plans to file for approval of entrectinib, a drug the Swiss firm acquired when it bought San Diego, CA-based Ignyta for $1.7 Roche’s Genentech unit provided updated data pooled from three early and mid-stage studies called STARTRK-1, STARTRK-2, and ALKA. billion last year. Roche said in a statement 77.4

San Diego 65

San Diego Study News Blogging 65

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

MAY 5, 2020

The decision to end work on the drug, KO-947, comes after San Diego-based Kura (NASDAQ: KURA ) was successful in lifting a partial clinical hold placed on a Phase 1 trial of the drug earlier this year by the FDA following a serious side effect experienced by one patient in the study.

San Diego 63

San Diego Study Develop Development 63

Xconomy

SEPTEMBER 9, 2019

Based on the results, the San Diego company said it would end the study early and seek a meeting with the regulator to discuss filing next year for approval in dementia-related psychosis. Pimavanserin was approved in 2016 as a treatment for psychosis associated with.

San Diego 74

San Diego Study Report Company 74

Xconomy

APRIL 18, 2018

John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup he’s leading has raised $2.66 The biotech, 10xBio, announced earlier this month that the FDA had approved its application to begin clinical trials in Phase 1b/2a studies testing the unnamed injectable drug.

San Diego 72

San Diego Study Entrepreneur Startup 72

Xconomy

DECEMBER 17, 2018

The news sent the San Diego, CA-based biotech’s stock plunging 40 percent. In June, the company said 10 of 37 patients with localized prostate cancer in its Phase 2b study who received the treatment reported a clinically significant response.

Slides 72

Slides San Diego Study News 72

Xconomy

NOVEMBER 3, 2017

Plante is a technology industry veteran in San Diego who has served as the CEO of Bel-Tronics, and as the founding CEO of SmartDrive Systems and Pathway Genomics. Studies in mice have. Thynk Capital founder and principal Jim Plante also is Klotho’s founder and CEO.

San Diego 85

San Diego Study Capital Technology 85

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

NOVEMBER 27, 2018

Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH.

San Diego 67

San Diego Study Research Organization 67

Xconomy

MARCH 20, 2018

San Diego, CA-based Arena (NASDAQ: ARNA ) said late Monday that its experimental compound etrasimod has succeeded in a Phase 2 trial in patients with moderate-to-severe ulcerative colitis, a form of inflammatory bowel disease. The main goal of the study was an improvement, Read more » Reprints | Share:

San Diego 57

San Diego Study Blogging 57